Medicare and cost-effectiveness analysis.

In this article, the authors discuss the obstacles to the use of cost-effectiveness analysis in Medicare decisions about coverage. They argue that policymakers could avert the impending financial crisis facing Medicare by incorporating cost-effectiveness analysis into a comprehensive strategy to allocate health care resources more rationally.

[1]  L. Goldman.  Cost-effectiveness in a flat world--can ICDs help the United States get rhythm? , 2005, The New England journal of medicine.

[2]  Douglas K Owens,et al.  Cost-effectiveness of implantable cardioverter-defibrillators. , 2005, The New England journal of medicine.

[3]  P. Danzon,et al.  Alternative strategies for Medicare payment of outpatient prescription drugs--Part B and beyond. , 2005, The American journal of managed care.

[4]  M. Mcclellan,et al.  Medicare coverage of ICDs. , 2005, The New England journal of medicine.

[5]  S. Jauhar,et al.  The Economics of ICDs. , 2004, The New England journal of medicine.

[6]  L. Stevenson.  Left ventricular assist devices as destination therapy for end-stage heart failure , 2004, Current treatment options in cardiovascular medicine.

[7]  R. Atlas.  The role of PBMs in implementing the Medicare prescription drug benefit. , 2004, Health affairs.

[8]  M. Drummond,et al.  Inclusion of cost effectiveness in licensing requirements of new drugs : The fourth hurdle , 2017 .

[9]  J. Newhouse.  Financing Medicare in the next administration. , 2004, The New England journal of medicine.

[10]  Peter J. Neumann,et al.  Using cost-effectiveness analysis to improve health care: opportunities and barriers. , 2004 .

[11]  M. Rawlins.  NICE work--providing guidance to the British National Health Service. , 2004, The New England journal of medicine.

[12]  Anthony J Culyer,et al.  National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.

[13]  S. Tunis.  Why Medicare has not established criteria for coverage decisions. , 2004, The New England journal of medicine.

[14]  M. Gillick,et al.  Medicare coverage for technological innovations--time for new criteria? , 2004, The New England journal of medicine.

[15]  A. Garber.  Cost-effectiveness and evidence evaluation as criteria for coverage policy. , 2004, Health affairs.

[16]  S. Tunis.  Economic analysis in healthcare decisions. , 2004, The American journal of managed care.

[17]  P. Neumann.  Why don't Americans use cost-effectiveness analysis? , 2004, The American journal of managed care.

[18]  R. Petersen,et al.  The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994 , 2004, Neurology.

[19]  D. Stryer,et al.  Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. , 2003, JAMA.

[20]  B. O'brien,et al.  Cost‐Effectiveness of the Implantable Cardioverter Defibrillator: , 2003, Journal of cardiovascular electrophysiology.

[21]  G. Gazelle,et al.  Cost-effectiveness of PET in the diagnosis of Alzheimer disease. , 2003, Radiology.

[22]  Ruth Etzioni,et al.  Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. , 2003, The New England journal of medicine.

[23]  Stephen Chapman,et al.  Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care , 2003, BMJ : British Medical Journal.

[24]  P. Neumann,et al.  Do HEDIS measures reflect cost-effective practices? , 2002, American journal of preventive medicine.

[25]  Joseph S. Pliskin,et al.  Health Economic Evaluations: The Special Case of End-Stage Renal Disease Treatment , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  S. Foote.  Why Medicare Cannot Promulgate a National Coverage Rule: A Case of Regula Mortis , 2002, Journal of health politics, policy and law.

[27]  S. Jencks,et al.  Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. , 2003, JAMA.

[28]  G. Adler,et al.  Screening for Osteoporosis and Colon Cancer under Medicare. (MCBS Highlights) , 2002 .

[29]  J R Hodges,et al.  The prevalence of frontotemporal dementia , 2002, Neurology.

[30]  T. Dent,et al.  From guidance to practice: Why NICE is not enough , 2002, BMJ : British Medical Journal.

[31]  A. Mitchell.  ANTIPODEAN ASSESSMENT , 2002, International Journal of Technology Assessment in Health Care.

[32]  Norman Daniels,et al.  Setting Limits Fairly: Can We Learn to Share Medical Resources? , 2002 .

[33]  R. Blendon,et al.  How interested are Americans in new medical technologies? A multicountry comparison. , 2001, Health affairs.

[34]  Jeffrey R. Harris,et al.  Priorities among recommended clinical preventive services. , 2001, American journal of preventive medicine.

[35]  James C. Robinson,et al.  The end of managed care. , 2001, JAMA.

[36]  S. Walker.  Using internet to access confidential patient records , 2001, BMJ : British Medical Journal.

[37]  R. Walker.  The failings of NICE. "Spinning" is not nice. , 2001, BMJ.

[38]  M D Rawlins,et al.  The failings of NICE , 2001, BMJ : British Medical Journal.

[39]  G. Fonarow,et al.  Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3 , 2001, Circulation.

[40]  L. Goldman,et al.  Health and Economic Benefits of Increased β-Blocker Use Following Myocardial Infarction , 2000 .

[41]  Richard Smith,et al.  The failings of NICE , 2000, BMJ : British Medical Journal.

[42]  J. Avorn,et al.  Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction , 2000, Annals of Internal Medicine.

[43]  D. Rennie,et al.  Pharmacoeconomic analyses: making them transparent, making them credible. , 2000, JAMA.

[44]  A J Moskowitz,et al.  Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. , 1997, JAMA.

[45]  D. Rowland,et al.  Voters and health care in the 1996 election. , 1997, JAMA.

[46]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[47]  M. Weinstein,et al.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[48]  R. G. Evans.  Manufacturing Consensus, Marketing Truth: Guidelines for Economic Evaluation , 1995, Annals of Internal Medicine.

[49]  K. Nichol,et al.  The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. , 1994, The New England journal of medicine.

[50]  J P Kassirer,et al.  The journal's policy on cost-effectiveness analyses. , 1994, The New England journal of medicine.

[51]  L. Goldman,et al.  Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. , 1991, JAMA.

[52]  M. Stanton.  Implantable cardioverter defibrillators: an excellent case study. , 2005, Health affairs.

[53]  G. Gazelle,et al.  Medicare's national coverage decisions, 1999-2003: quality of evidence and review times. , 2005, Health affairs.

[54]  N. Olchanski,et al.  Growth and quality of the cost-utility literature, 1976-2001. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[55]  Peter J Neumann,et al.  Evidence-based and value-based formulary guidelines. , 2004, Health affairs.

[56]  U. Reinhardt.  An information infrastructure for the pharmaceutical market. , 2004, Health affairs.

[57]  J. Greene,et al.  Use of Preventive Care Services, Beneficiary Characteristics, and Medicare HMO Performance , 2001, Health care financing review.